Unaltered strong immunohistochemical expression of CD44-v6 and -v5 isoforms during development and progression of oral squamous cell carcinomas

Journal of Oral Pathology and Medicine

Volumn 25, Issue 9, 1996, Pages 502-506

  Piffkò, Jòzsef ^a   Bànkfalvi, Àgnes ^b   Klauke, Kariona ^b   Dreier, Rita ^b   Joos, Ulrich ^a   Böcker, Werner ^b   Schmid, Kurt Werner ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

CD44; immunohistochemistry; oral cancer; prognosis; wet autoclave antigen retrieval

Indexed keywords

EID: 0030267708     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.1996.tb00305.x     Document Type: Article

References (31)

1. HAYNES BF, LIAO H-X, PATTON KL The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells 1991; 3: 347-50.
2. RUIZ P, SCHWÄRZLER C, GÜNTHERT U. CD44 isoforms during differentiation and development. BioEssays 1994; 17: 17-24.
3. SPRINGER TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14.
4. THOMAS L, BYERS HR, VINK J, STAMEN-KOVIC I CD44H regulates tumor cell migration on hyaluronate-coated substrates. J Cell Biol 1992; 118: 971-7.
5. GÜNTHERT U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993; 184: 47-63.
6. GÜNTHERT U, HOFMANN M, RUDY W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
7. GÜNTHERT U, STAUDER R, MAYER B, TERPE H-J, FINKE L, FRIEDRICHS K. Are CD44 variant isoforms involved in human tumour progression? Cancer Surveys 1995; 24: 19-41.
8. ZÖLLER M, KAUFMANN M. CD44 and metastasis. Onkologie 1994, 17: 114-22.
9. WIELEGA VJM, HEIDER KH, OFFERHAUS JA, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53: 4754-6.
10. HEIDER KH, DÄMMRICH J, SKROCH-ANGEL P, et al. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993; 53: 4197-203.
11. KAUFMANN M, HEIDER KH, SINN HP. VON MINCKWITZ G, PONTA FH, HERRLICH P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345: 615-9.
12. FUJITA N, YAEGASHI N, IDE Y, et al. Expression of CD44 in normal versus tumor endometrial tissues: possible implications of reduced expression of CD44 in lymphvascular space involvement of cancer cells. Cancer Res 1994; 54: 3922-5.
13. STAUDER R, EISTERER A, THALER J, GÜNTHERT U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995; 85: 2885-99.
14. MULDER J-W, KRUYT P, SEWNATH M, et al. Colorectal cancer prognosis and expression of exon-v6 containing CD44 proteins. Lancet 1994; 344: 1470-2.
15. KORETZ K, MÖLLER P, LEHNERT T, HINZ U, OTTO HF, HERFARTH C. Effect of CD44v6 on survival in colorectal carcinoma Lancet 1995; 345: 327-8.
16. TERPE HJ, STÖRKEL S, ZIMMER U, et al. Expression of CD44 isoforms in renal cell tumors: positive correlation to tumor progression. Am J Pathol 1996; 148: 453-63
17. FRIEDRICHS K, FRANKE F, LISBOA B-W, et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995; 55: 5424-33.
18. HONG RL, PU YS, CHU JS, LEE WJ, CHEN YC, WU CW. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett 1995; 89: 81-7.
19. SALMI M, GRÖN-VIRTA K, SOINTU P, GRENMAN R, KALIMO H. JALKANEN S. Regulated expression of exon v6 containing isoforms of CD44 in man: down-regulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 1993; 122: 431-42.
20. TERPE HJ, STARK H, PREHM P, GÜNTHERT U. CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues. Histochemistry 1994; 101: 79-89.
21. HEIDER KH, MULDER JWR, OSTERMANN E, et al. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur J Cancer 1995; 31A: 2385-91.
22. HERMANEK P, SOBIN LH. TNM classification of malignant tumours. Geneva: International Union Against Cancer, 1992; 15-20.
23. WAHI PN, COHEN B, LUTHRA U. Histopathological typing of oral and oropharyngeal tumours. Geneva: WHO, 1971; 17-8.
24. BÀNKFALVI À, NAVABI B, BIER B, BÖCKER W, JASANI B, SCHMID KW. Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol 1994; 174: 223-8.
25. BIER B, BANKFALVI A, GROTE L, et al. Wet autoclave pretreatment for immunohistochemical demonstration of oestrogen receptors in routinely processed breast carcinoma tissue. Histochemical J 1995; 27: 148-54.
26. MACKAY CR, TERPE HJ, STAUDER R, MARSTON WL, STARK H, GÜNTHERT U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994; 124: 71-82.
27. TAKADA M, YAMAMOTO M, SAITOH Y. The significance of CD44 in human pancreatic cancer: II. The role of CD44 in human pancreatic adenocarcinoma invasion. Pancreas 1994; 9: 753-7.
28. ARIZA A, LOPEZ D, MATE JL, et al. Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. Hum Pathol 1995; 26: 1144-7.
29. WATT FM. Selective migration of terminally differentiating cells from the basal layer of cultured human epidermis. J Cell Biol 1984; 98: 16-21.
30. BENNETT KL, JACKSON DG, SIMON JC, et al CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995; 128: 687-98.
31. FAk) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 1994; 269: 31807-13.